GUTS
Fractyl Health, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$0.70
+1.25%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
Market Cap
$110.77M
MomentumView details →
1D Return
+1.25%
YTD Return
−68.39%
RSI (14)
47.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
Market Cap
$110.77M
RSI (14)
47.1
MomentumView details →
1D Return
+1.25%
YTD Return
−68.39%
SummaryUpdated Jun 1, 2026
Fractyl Health, Inc. (NASDAQ:GUTS) is a metabolic therapeutics company founded in 2010 and based in Lexington, Massachusetts. The company was formerly known as Fractyl Laboratories Inc. before changing its name in June 2021. Fractyl went public on NASDAQ in 2024, focusing on developing innovative therapies for type 2 diabetes and obesity. The company operates two main therapeutic platforms: the Revita procedural therapy system and the Rejuva gene therapy platform, both targeting the growing global epidemic of metabolic diseases.
Similar companies
Latest newsMore news →
A class action lawsuit was filed against Fractyl Health, Inc. on behalf of investors who purchased securities between January 13, 2025 and January 29, 2026.1d agoGlancy Prongay Wolke & Rotter LLP announced a securities fraud lawsuit on behalf of Fractyl Health, Inc. shareholders who suffered losses, related to the company's disclosure of REMAIN-1 Midpoint Cohort data on January 29, 2026.3d agoFractyl Health announced that its Revita endoscopic procedure demonstrated durable weight-maintenance results one year after patients discontinued GLP-1 therapy.25d ago